Press releaseGlobe Newswire
Editas Medicine
EDIT · NASDAQ
$2.58+$0.16 (+6.61%)TodayMarket closed ·
Prev close $2.42
Latest news
- Press releaseGlobe Newswire
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
- Press releaseGlobe Newswire
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
- Press releaseGlobe Newswire
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
- NewsAvi Kapoor
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
- Press releaseGlobe Newswire
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
- Press releaseGlobe Newswire
Editas Medicine Announces First Quarter 2026 Results and Business Updates
- News
Editas Medicine Q4 Earnings Assessment
- Press releaseGlobe Newswire
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
- Press releaseGlobe Newswire
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
- Press releaseACCESS Newswire
Genflow Biosciences PLC Announces Directorate Change
- Press releaseGlobe Newswire
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
- NewsAkanksha Bakshi
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
- Press releasePRNewswire
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
- News
Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsVandana Singh
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Editas Medicine Announces First Quarter 2025 Results and Business Updates
- News
Earnings Scheduled For May 12, 2025
- Press releaseGlobe Newswire
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
- News
Earnings Scheduled For March 5, 2025
- News
12 Analysts Have This To Say About Editas Medicine
- News
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
- News
Where Editas Medicine Stands With Analysts
- NewsAvi Kapoor
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.